Amendments to the Claims:

1. (Currently Amended) A compound having indoleamine 2,3 dioxygenase (IDO) inhibitory activity, said compound having the ~~a formula selected from the group consisting of~~ formula ~~(I)~~:



(I)

, wherein R_1 is H or lower alkyl; ~~R_2 is H; R_3 is selected from the group consisting of: (a)~~



~~, wherein R_A and R_B are independently selected from the group of H and hydrocarbyl; (b)~~



~~, wherein R_C is selected from the group of H and hydrocarbyl; (c)~~



~~; (d)~~



~~; (e)~~



~~, wherein n is a whole number from 1 to 10 and R_D is a~~

~~carboline substituent of the formula:~~  ~~; and (f)~~  ~~wherein R_A and R_B are independently selected from the group of H and hydrocarbyl; or~~ R_2 and R_3 are joined together and represent part of a ring which is fused to the pyrrole moiety of formula (I)

and which is selected from the group of:  ~~(i),~~ ~~(ii),~~(i) and ~~(iii),~~ (ii) wherein R_E is a hydrocarbyl or alkyl-Q, Q representing a substituent of the formula:

 , the compound of formula (I) being ~~a β-carboline derivative when R_2 and R_3 joined together represent (i),~~ a brassilexin derivative when R_2 and R_3 joined together represent ~~(ii)~~ (i), and an N-substituted brassilexin derivative when R_2 and R_3 joined together represent ~~(iii)~~ (ii); X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and ~~when R_2 and R_3 are joined together and represent part of a ring system,~~ Y may also be isothiocyanate~~; with the proviso that formula (I) does not include a compound selected from the group of: 3-(N-methyl-thiohydantoin)-indole, 3-(N-phenyl-thiohydantoin)-indole, 3-(N-allyl-thiohydantoin)-indole, 5-methyl-brassinin, brassinin, brassilexin, β-carboline, 3-butyl-β-carboline, 6-fluoro-3-carbomethoxy-β-carboline, 6-isothiocyanate-3-carbomethoxy-β-carboline, 3-propoxy-β-carboline, 3-carboxy-β-carboline, 3-carbopropoxy-β-carboline, and 3-carbo-tert-butoxy-β-carboline; and~~

~~formula (II):~~ 

~~, wherein X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and with the proviso that formula (II) does not include 3-amino-2-naphthoic acid.~~

2. (Currently Amended) A pharmaceutical composition ~~for the treatment of cancer~~ comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier medium.

3.-13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition ~~for the treatment of a cancer, said composition~~ comprising an effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one signal transduction inhibitor (STI) in a pharmaceutically acceptable carrier medium, wherein said at least one IDO inhibitor is ~~selected from the group of~~ a compounds having the ~~strature of~~ formula ~~(I)~~:



(I)

, wherein R_1 is H or lower alkyl; ~~R_2 is H; R_3 is selected from the group consisting of:~~



~~(a), wherein R_A and R_B are independently selected from the group of H~~



~~and hydrocarbyl;~~ ~~(b), wherein R_C is selected from the group of H and~~







~~hydrocarbyl;~~ ~~(c);~~ ~~(d);~~ ~~(e),~~ ~~wherein n is a whole number from 1 to 10 and R_D is a carboline substituent of the formula:~~





~~; and (f)~~ ~~, wherein R_A and R_B are independently selected from the group of H and hydrocarbyl; or~~ R_2 and R_3 are joined together and represent part of a ring which is fused to the pyrrole moiety of formula (I) and which is selected from the group

of: ~~(i),~~ ~~(ii)~~ (i), and ~~(iii)~~ (ii), wherein R_E is a hydrocarbyl or alkyl-Q, Q representing a substituent of the formula:



, the compound of formula (I) being ~~a β-carboline derivative when R_2 and R_3 joined together represent (i),~~ a brassilexin derivative when R_2 and R_3 joined together represent ~~(ii)~~ (i) and an N-substituted

brassilexin derivative when R_2 and R_3 joined together represent ~~(iii)~~ (ii); X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and ~~when R_2 and R_3 are joined together and represent part of a ring system,~~ Y may also be isothiocyanate~~,; with the proviso that formula (I) does not include a compound selected from the group of: 3-(N-methyl-thiohydantoin)-indole, 3-(N-phenyl-thiohydantoin)-indole, 3-(N-allyl-thiohydantoin)-indole, 5-methyl-brassinin, brassinin, brassilexin, β-carboline, 3-butyl-β-carboline, 6-fluoro-3-carbomethoxy-β-carboline, 6-isothiocyanate-3-carbomethoxy-β-carboline, 3-propoxy-β-carboline, 3-carboxy-β-carboline, 3-carbopropoxy-β-carboline, and 3-carbo-tert-butoxy-β-carboline; and~~



~~formula (II):~~ ~~, wherein X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and with the proviso that formula (II) does not include 3-amino-2-naphthoic acid~~.

15. (Original) The pharmaceutical composition of claim 14, wherein said at least one STI is selected from the group consisting of bcr/abl kinase inhibitors, epidermal growth factor (EGF) receptor inhibitors, her-2/neu receptor inhibitors, farnesyl transferase inhibitors (FTIs), inhibitors of Akt family kinases or the Akt pathway, and cell cycle kinase inhibitors.

16. (Original) The pharmaceutical composition of claim 15, wherein said at least one STI is selected from the group consisting of STI 571, SSI-774, C225, ABX-EGF, trastuzumab, L-744,832, rapamycin, LY294002, flavopiridal, and UNC-01.

17. (Original) The pharmaceutical composition of claim 16, wherein said at least one STI is L-744,832.

18.-34. (Cancelled)

35. (Currently Amended) A pharmaceutical composition ~~for the treatment of a cancer, said composition~~ comprising an effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent in a pharmaceutically acceptable carrier medium, wherein said at least one IDO inhibitor is selected from the group of compounds having ~~the structure of~~ formula ~~(I)~~:



(I)

, wherein R_1 is H or lower alkyl; ~~R_2 is H; R_3 is selected from the group consisting of:~~



~~(a), wherein R_A and R_B are independently selected from the group of H and hydrocarbyl;~~



~~(b), wherein R_C is selected from the group of H and hydrocarbyl;~~



~~(c);~~



~~(d);~~



~~(e), wherein n is a whole number from 1 to 10 and R_D is a carboline substituent of the formula:~~





~~; and (f)~~ ~~, wherein R_A and R_B are independently selected from the group of H and hydrocarbyl; or~~ R_2 and R_3 are joined together and represent part

of a ring which is fused to the pyrrole moiety of formula (I) and which is selected from the group



of: ~~(i),~~ ~~(iii),~~(i) and ~~(iii)~~ (ii), wherein R_E is a hydrocarbyl or



alkyl-Q, Q representing a substituent of the formula: , the compound of formula (I) being ~~a β-carboline derivative when R_2 and R_3 joined together represent (i),~~ a brassilexin derivative when R_2 and R_3 joined together represent ~~(ii)~~ (i), and an N-substituted brassilexin derivative when R_2 and R_3 joined together represent ~~(iii)~~ (ii); X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and ~~when R_2 and R_3 are joined together and represent part of a ring system,~~ Y may also be isothiocyanate; ~~with the proviso that formula (I) does not include a compound selected from the group of: 3-(N-methyl-thiohydantoin)-indole, 3-(N-phenyl-thiohydantoin)-indole, 3-(N-allyl-thiohydantoin)-indole, 5-methyl-brassinin, brassinin, brassilexin, β-carboline, 3-butyl-β-carboline, 6-fluoro-3-carbomethoxy-β-carboline, 6-isothiocyanate-3-carbomethoxy-β-carboline, 3-propoxy-β-carboline, 3-carboxy-β-carboline, 3-carbopropoxy-β-carboline, and 3-carbo-tert-butoxy-β-carboline; and~~



~~formula (II):~~ ~~, wherein X, Y, and Z may be the same or different and are selected from the group consisting of H, halogen, NO_2, and hydrocarbyl; and with the proviso that formula (II) does not include 3-amino-2-naphthoic acid~~.

36. (Original) The pharmaceutical composition of claim 14, wherein said at least one

chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®), cisplatin, docetaxol, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epothilone derivatives.

37. (Original) The pharmaceutical composition of claim 15, wherein said at least one chemotherapeutic agent is paclitaxel.